How to appeal your Medicare (Original + Advantage) experimental or investigational denial
Carriers commonly deny coverage by labeling a treatment 'experimental' or 'investigational', a designation that bypasses the usual medical-necessity analysis. This guide is specific to Medicare (Original + Advantage) appeals.
Why Medicare (Original + Advantage) denies experimental or investigational
Medicare is a federal program with two delivery modes, Original (fee-for-service Part A/B + Part D drug plans) and Advantage (private MA-C plans). Each has its own appeal ladder, and rights are stronger than most beneficiaries realize.
For experimental or investigational specifically: Carriers commonly deny coverage by labeling a treatment 'experimental' or 'investigational', a designation that bypasses the usual medical-necessity analysis. These denials are appealable, and many reverse when peer-reviewed evidence, compendia listings, or clinical-trial data are presented.
FDA approval for the indication, recognized compendia (NCCN, AHFS-DI, DrugDex), and CMS National Coverage Determinations defeat an 'experimental or investigational' label.
What Medicare (Original + Advantage) denies for experimental or investigational
The experimental or investigational services most often denied:
- Off-label oncology regimens
- Newer CAR-T and cellular therapies
- Proton beam therapy
- Genetic and biomarker testing (next-generation sequencing)
- Surgical techniques deemed novel
- Compassionate-use and expanded-access drugs
Why experimental or investigational claims get denied
A typical Medicare (Original + Advantage) experimental or investigational denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:
- Treatment is not specifically FDA-approved for the indication
- Plan policy bulletin lists the service as investigational
- No randomized controlled trial cited in plan's policy
- Service is not in a recognized compendium for the diagnosis
The Medicare (Original + Advantage) appeal process
Appeal levels: 5 federal levels. Each has its own deadline and a minimum dollar threshold for the higher levels (ALJ requires $200+ in 2026).
Carrier timing: 120 days from denial for level 1 (Original) or 60 days for Medicare Advantage. Each subsequent level: 60 days.
Experimental timing: Internal appeal: 180 days from denial. External review: typically 4 months / 120 days from final internal denial. Expedited urgent review: 72 hours.
What we know about Medicare (Original + Advantage): Medicare cases require a CMS-1696 Appointment of Representative form for us to act on your behalf. We provide this at intake.
Common Medicare (Original + Advantage) denial patterns for experimental or investigational
- Original Medicare: 5-level appeal. Redetermination by MAC → reconsideration by QIC → ALJ hearing → Medicare Appeals Council → federal district court. The QIC and ALJ levels reverse a substantial share of denials when properly briefed.
- Medicare Advantage: identical 5-level ladder. MA plans must follow the same federal appeal structure as Original Medicare. Plan-level reconsideration → Independent Review Entity (Maximus) → ALJ → Council → federal court.
- Part D drug coverage denials. Part D appeals follow a separate but parallel ladder. Tiering exceptions and formulary exceptions are filed before a coverage determination challenge.
How to win your Medicare (Original + Advantage) experimental or investigational appeal
Strategy for experimental or investigational: Identify the plan's exact 'experimental/investigational' policy bulletin and rebut it point-by-point. Cite NCCN, ASCO, AHFS-DI, DrugDex, or other recognized compendia for the indication. Attach peer-reviewed literature and any clinical-trial enrollment data. Many state external review programs apply a heightened standard for E/I denials, once the case reaches external review, the IRO physician panel often overturns.
Filed against Medicare (Original + Advantage), that strategy rides on this procedural spine:
- Procedural-rights anchor. Every Medicare (Original + Advantage) denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
- Criteria-disclosure demand. Medicare (Original + Advantage) frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
- Controlling-standard citation. FDA approval for the indication, recognized compendia (NCCN, AHFS-DI, DrugDex), and CMS National Coverage Determinations defeat an 'experimental or investigational' label.
- Treating-provider attestation. A letter from the treating physician addressing each criterion in Medicare (Original + Advantage)'s own policy language. This is the single strongest evidentiary element.
- Requested action. A specific demand to reverse the experimental or investigational denial and approve the service, not a general "please reconsider."
Documents you'll need for your Medicare (Original + Advantage) experimental or investigational appeal
- Denial letter (with plan's E/I policy bulletin)
- Treating physician's letter of medical necessity
- Peer-reviewed literature supporting the therapy
- Compendium entry (NCCN, ASCO, AHFS-DI, DrugDex)
- Pathology / diagnostic report
What a experimental or investigational appeal can recover
Typical recovery for experimental or investigational cases runs $5,000 - $500,000+ depending on therapy. The exact figure depends on the specific service and your plan's contracted rates.
Medicare (Original + Advantage) experimental or investigational appeals: frequently asked questions
Can I appeal an 'experimental or investigational' denial from Medicare (Original + Advantage)?
Yes, and these reverse often at external review. Identify the plan's exact experimental/investigational policy bulletin and rebut it point by point with FDA approval for the indication, recognized compendia, and peer-reviewed evidence.
What beats an 'experimental' label?
FDA approval for the specific indication, a recognized compendium entry (NCCN, AHFS-DI, DrugDex), a CMS national coverage determination, and peer-reviewed literature. Many state external-review programs apply a heightened standard for these denials.
How long do I have for an experimental-denial appeal?
Internal appeals are due within 180 days. External review is typically available within 4 months (120 days) of the final internal denial, and urgent cases qualify for 72-hour expedited review.
Why does Medicare (Original + Advantage) call a standard treatment experimental?
Usually because the therapy is not specifically FDA-approved for that indication, the plan's bulletin lists it as investigational, or no randomized trial is cited in the policy. A compendium entry for your diagnosis directly contradicts that classification.
What Apellica does for Medicare (Original + Advantage) experimental or investigational appeals
We file appeals against Medicare (Original + Advantage) specifically configured to its internal review process. Every experimental or investigational appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.
Cost: $0 upfront. We work on contingency for Medicare (Original + Advantage) appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.
Start your Medicare (Original + Advantage) experimental or investigational appeal
Submit a 2-minute intake. A senior reviewer responds within one business day with the specific appeal strategy for your case.
Start free appeal review →Related Medicare (Original + Advantage) guides
- Medicare (Original + Advantage) surgery denials appeal guide
- Medicare (Original + Advantage) mri and imaging denials appeal guide
- Medicare (Original + Advantage) medication and prescription denials appeal guide
- Medicare (Original + Advantage) medicare denials appeal guide